FDA Approves Onivyde Combination for Metastatic Pancreatic Cancer
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 15, 2024 -- The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) as a first-line treatment for adults living with metastatic pancreatic adenocarcinoma (mPDAC).
The FDA previously approved an Onivyde regimen (Onivyde plus fluorouracil and leucovorin) for mPDAC following disease progression with gemcitabine-based therapy.
The approval was based on efficacy and safety data from NAPOLI 3, a randomized, open-label, phase III pivotal trial that enrolled 770 adults with mPDAC and without prior treatment from 187 trial site locations in 18 countries. The trial revealed that NALIRIFOX provided a statistically significant improvement in median overall survival of 11.1 months versus 9.2 months in nab-paclitaxel and gemcitabine-treated patients (hazard ratio, 0.84). NALIRIFOX was also associated with a statistically significant improvement in median progression-free survival (7.4 months versus 5.6 months for nab-paclitaxel- and gemcitabine-treated patients; hazard ratio, 0.70).
"With each new approved treatment, there is more hope for those who will be diagnosed in the future and people currently living with pancreatic cancer may have more time with their loved ones," said Julie Fleshman, president and CEO of Pancreatic Cancer Action Network, in a statement.
Approval of Onivyde was granted to Ipsen.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
American Association for Cancer Research, April 5-10
The annual meeting of the American Association for Cancer Research was held this year from April 5 to 10 in San Diego, drawing approximately 19,000 participants from around the...
Subclassification Can Tailor Surveillance for Pancreatic Adenocarcinoma
WEDNESDAY, April 17, 2024 -- Subclassification of individuals at high risk for pancreatic adenocarcinoma (PC) can enable the development of surveillance approaches better tailored...
AACR: Exosome-Based miRNA Assay Can Detect Pancreatic Cancer
MONDAY, April 8, 2024 -- An exosome-based liquid biopsy assay can distinguish patients with pancreatic ductal adenocarcinoma (PDAC) from healthy donors (HDs), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.